Fulgent Therapeutics

About Fulgent Therapeutics

In 2012 Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581) and in mid-2013 it became CAP accredited. Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in the future. Using Next Generation Sequencing (NGS) technology we are developing a new series of panel based test for our clients. Our investment is more than just the equipment. Leading our development is a dedicated team of researchers and scientists. We realize that without the people we are just a supplier. Our goal is to provide a customized product based on the needs of the doctor and the patient. This personalized approach to diagnostics can provide meaningful data as it relates to therapies and diagnosis.